Research Article Details
| Article ID: | A23007 |
| PMID: | 24119357 |
| Source: | Acad Radiol |
| Title: | MRI-diagnosed nonalcoholic fatty liver disease is correlated to insulin resistance in adolescents. |
| Abstract: | RATIONALE AND OBJECTIVES: To evaluate the presence of nonalcoholic fatty liver disease (NAFLD) in eutrophic and obese adolescents with magnetic resonance imaging (MRI) and its relationship to insulin resistance and other potential biomarkers. MATERIALS AND METHODS: A total of 50 adolescents (aged 11-17 years), including 24 obese and 26 eutrophic adolescents, were evaluated using MRI exams for NAFLD diagnosis. Blood analysis was performed to measure glucose, insulin, total cholesterol, high-density lipoprotein cholesterol, triglycerides, fibrinogen, aminotransferases, alkaline phosphatase, gamma-gt, and C-reactive protein. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index was also calculated. Laboratory test results and anthropometric assessment were statistically analyzed to determine potential correlation with NAFLD prevalence. RESULTS: The prevalence of NAFLD among the obese was significantly higher (83.3%; CI 95: 64.5-94.5%) than that of the eutrophic group (19.2%; CI 95: 7.4-37.6%). In multivariate analysis, only HOMA-IR was an independent risk factor for diagnosis NAFLD using MRI. Compared to eutrophic adolescents, the obese adolescents had significantly higher levels for all parameters measured except for total and high-density lipoprotein cholesterol, which were significantly lower. CONCLUSION: The prevalence of NAFLD was 19.2% among eutrophic patients and 83.3% among obese patients. Only HOMA-IR was determined to be an independent risk factor for NAFLD. |
| DOI: | 10.1016/j.acra.2013.08.016 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |